Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $13.1 million.

  • Dianthus Therapeutics' Accumulated Expenses rose 106.79% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 106.79%. This contributed to the annual value of $13.1 million for FY2024, which is 101.01% up from last year.
  • According to the latest figures from FY2024, Dianthus Therapeutics' Accumulated Expenses is $13.1 million, which was up 101.01% from $6.5 million recorded in FY2023.
  • Dianthus Therapeutics' Accumulated Expenses' 5-year high stood at $13.1 million during FY2024, with a 5-year trough of $6.5 million in FY2023.
  • Moreover, its 3-year median value for Accumulated Expenses was $6.6 million (2022), whereas its average is $8.7 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Accumulated Expenses fell by 1.57% in 2023 and then skyrocketed by 101.01% in 2024.
  • Over the past 3 years, Dianthus Therapeutics' Accumulated Expenses (Yearly) stood at $6.6 million in 2022, then fell by 1.57% to $6.5 million in 2023, then spiked by 101.01% to $13.1 million in 2024.